Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
biotech
europe top stories
4
×
life sciences
national blog main
national top stories
san francisco top stories
4
×
boston blog main
boston top stories
cancer
europe blog main
fda
indiana blog main
indiana top stories
national
new york top stories
novartis
san francisco blog main
biogen
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
genentech
new york blog main
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
accent therapeutics
aducanumab
alzheimer's disease
amblyotech
What
fda
4
×
drug
cancer
medicine
medicines
new
patients
therapy
activity
address
approval
approvals
approved
approves
atrophy
bio
biogen
blueprint
carries
certain
clamped
covid
daily
delays
designed
developing
economic
eisai
evrysdi
fast
flags
friday
genetic
green
higher
home
incidence
including
intended
ipo
Language
unset
Current search:
photo
×
fda
×
" san francisco top stories "
×
" europe top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks